<DOC>
	<DOC>NCT02933710</DOC>
	<brief_summary>The purpose of the study is to perform the re-examination of IMOJEV® in routine clinical settings in accordance with the Ministry of Food and Drug Safety regulation. Primary objective: - To describe the safety profile of the first dose of IMOJEV® administered under routine health care visit as primary vaccination or as booster.</brief_summary>
	<brief_title>Postmarketing Surveillance Study for IMOJEV® in Republic of Korea</brief_title>
	<detailed_description>Subjects aged 12 months of age and older and who are given study vaccine during routine health-care visits will be enrolled in the study. They will also receive one dose of booster 12 to 24 months after the primary dose. No study vaccine will be supplied or administered as part of this study, subjects will be monitored following routine vaccine administration in clinical settings.</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Informed consent form signed by the subject (for subjects 19 years old and above) or the parent(s) or other legal representative (for subjects under 19 years of age) Receipt of the first dose of IMOJEV® (on the day of inclusion) according to approved local insert paper. Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or a medical procedure. Subjects who already participated in this study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Japanese encephalitis</keyword>
	<keyword>IMOJEV®</keyword>
	<keyword>Japanese encephalitis chimeric virus vaccine</keyword>
</DOC>